Aurobindo gets FDA nod for acid reflux drug
City-based Aurobindo Pharma on Thursday said it had received final approval from the US health regulator to manufacture and market Famotidine Tablets used for acid reflux treatment.
Hyderabad: City-based Aurobindo Pharma on Thursday said it had received final approval from the US health regulator to manufacture and market Famotidine Tablets used for acid reflux treatment.
"The company has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Famotidine Tablets," the company said in a statement. Approval has been granted for Famotidine Tablets of 20 mg and 40 mg strengths.
The approved ANDA (Abbreviated New Drug Application) is bioequivalent and therapeutically equivalent to the reference listed drug product Pepcid Tablets, 20 mg and 40 mg, of Valeant Pharmaceuticals International, Inc, it added. Famotidine Tablets is used for the short-term treatment of gastroesophageal reflux disease and active duodenal ulcer.
Quoting IMS data, Aurobindo Pharma said the approved product had an estimated market size of $29 million for the twelve months ending October 2015. This is the 54th ANDA to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products, the company said.
- Rajinikanth gets inked on the right hand, authorities sought a report
- Modi lashes out at Mamata Banerjee, says she lost her sleep just after two phases of polling
- Bangalore logs a turnout of 54.1%, worse than 2014 polls, which was 56%
- AAP says no to alliance just in Delhi, talk of tie-up in Haryana over: Sisodia
- Modi a fool: Siddaramaiah slams PM for taking advantage of surgical strikes